Mar 9, 2017 • 7:00 am EST Corbus Pharmaceuticals Reports 2016 Financial Results and Provides 2017 Business Update
Mar 8, 2017 • 8:00 am EST Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways
Mar 1, 2017 • 7:30 am EST Corbus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference
Feb 23, 2017 • 8:05 am EST Corbus Pharmaceuticals Announces Preclinical Data Demonstrating JBT-101 Reduces Inflammation in Alveolar Macrophages from Cystic Fibrosis Patients
Feb 21, 2017 • 7:30 am EST Corbus Pharmaceuticals to Host Research and Development Day on March 13, 2017
Jan 17, 2017 • 7:30 am EST Corbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union
Dec 29, 2016 • 7:30 am EST Corbus Pharmaceuticals Announces Completion of Phase 2 Study of JBT-101 (Resunab) for the Treatment of Cystic Fibrosis